Physician profile
Mimi Van
NPI 1801298294
$3,573.10
in general payments reported to CMS, 2019-2025
15 companies · $27.67 in 2025
The $27.67 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,489 · 2020: $313 · 2021: $113 · 2022: $432 · 2023: $51.88 · 2024: $146 · 2025: $27.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,420.47 | 2019-2021 | |
| Abbvie INC. | $886.81 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.39 | 2019-2022 | |
| Gilead Sciences, INC. | $213.91 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.41 | 2020-2022 | |
| Intuitive Surgical, INC. | $116.94 | 2023-2024 | Da Vinci Surgical System |
| Allergan, INC. | $115.42 | 2019 | |
| Janssen Scientific Affairs, LLC | $113.70 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $48.25 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $44.68 | 2022 | |
| Nestle Healthcare Nutrition INC. | $43.62 | 2021 | |
| Pharmacosmos Therapeutics INC. | $25.38 | 2023 | Monoferric |
| Redhill Biopharma INC. | $17.13 | 2020 | |
| Madrigal Pharmaceuticals | $15.48 | 2024 | Resmetirom |
| Shire North American Group INC | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Van listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.